

Data Sheet

Product Name: Abagovomab
Cat. No.: CS-0620975
CAS No.: 792921-10-9
Target: Others
Pathway: Others
Solubility: 10 mM in DMSO

Abagovomab

BIOLOGICAL ACTIVITY:

Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, **CA-125**. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc)^{[1][2]}.

References:

[1]. Pfisterer J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006 Oct;17(10):1568-77.

[2]. Grisham RN, et al. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.

CAIndexNames:

Immunoglobulin G1, anti-(mouse OC 125) (mouse monoclonal ACA-125 clone 3D5 γ -chain), disulfide with mouse monoclonal ACA-125 clone 3D5 κ -chain, dimer

SMILES:

[Abagovomab]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA